Casey Stelter, MD
Family Medicine · Layton, UTNPI 1073607222
Payments from drug & device makers
Across 143 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$390
- Johnson & Johnson$219
- Astellas Pharma US Inc$216
- Novartis$145
- GSK$131
- Pfizer$117
- plus $1K from 30 others
What the payments were for
- Food & beverage$2,33294%
- Education$1556%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 29 | $390 |
| Johnson & Johnson | 13 | $219 |
| Astellas Pharma US Inc | 5 | $216 |
| Novartis | 7 | $145 |
| GSK | 9 | $131 |
| Pfizer | 6 | $117 |
| Amgen(2 entities) | 6 | $117 |
| Novo Nordisk | 6 | $88 |
| Supernus Pharmaceuticals, Inc. | 5 | $85 |
| Neurocrine Biosciences, Inc. | 4 | $82 |
| Inspire Medical Systems, Inc. | 3 | $74 |
| Abbott | 3 | $66 |
| Vanda Pharmaceuticals Inc. | 2 | $59 |
| Lundbeck LLC | 3 | $57 |
| Biogen | 4 | $57 |
| AstraZeneca | 4 | $55 |
| Amarin Pharma, Inc. | 3 | $50 |
| Alkermes, Inc. | 3 | $48 |
| Lilly USA, LLC | 3 | $44 |
| Cranial Technologies, Inc | 2 | $42 |
| Sanofi-aventis U.S. LLC | 3 | $41 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Baxter Healthcare | 1 | $37 |
| Merck | 1 | $25 |
| Antares Pharma, Inc. | 2 | $24 |
| Boston Scientific | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Acadia Pharmaceuticals Inc | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Gilead | 1 | $15 |
| Medtronic | 1 | $15 |
| Eisai Inc. | 1 | $14 |
| Nalpropion Pharmaceuticals LLC | 1 | $13 |
| Sumitomo Pharma America, Inc. | 4 | $12 |
How this compares
$2,487 in reported general payments places this provider in the 70th percentile of 928 family medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,581 | $508,278 |
| Invega SustennaPaliperidone Palmitate | 52 | $160,238 |
| TradjentaLinagliptin | 545 | $157,114 |
| AustedoDeutetrabenazine | 53 | $119,611 |
| Austedo XrDeutetrabenazine | 29 | $117,947 |
| JardianceEmpagliflozin | 322 | $113,372 |
| FarxigaDapagliflozin Propanediol | 308 | $106,377 |
| TrulicityDulaglutide | 101 | $94,105 |
| XifaxanRifaximin | 41 | $69,226 |
| NuedextaDextromethorphan Hbr/Quinidine | 85 | $67,479 |
| MyrbetriqMirabegron | 229 | $64,258 |
| XareltoRivaroxaban | 129 | $53,353 |
| MounjaroTirzepatide | 40 | $46,885 |
| Daptomycin | 22 | $44,157 |
| JanuviaSitagliptin Phosphate | 98 | $39,659 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $117 | $508,2781,581 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $38 | $237,55882 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto | $219 | $213,591181 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $44 | $140,990141 claims |
| AstraZenecaFarxiga, Lokelma | $55 | $119,172343 claims |
| Astellas Pharma US IncMyrbetriq | $216 | $64,258229 claims |
| AbbVieCreon, Linzess | $390 | $47,64778 claims |
| MerckJanuvia | $25 | $39,65998 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $131 | $37,41067 claims |
| Novo NordiskOzempic | $88 | $36,09133 claims |
| NovartisEntresto | $145 | $25,07753 claims |
| Sanofi-aventis U.S. LLCRenvela | $41 | $11,86833 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 928 family medicine providers in Utah.
Other family medicine in Layton
- Marc AndersonLayton$2.8M
- Jeffery DegrauwLayton$921K
- Kurtis WoolfLayton$224K
- Courtney NelsonLayton$190K
- David ButtersLayton$189K
- John HemmersmeierOgden$24.9M
- Judith KirsteinWest Jordan$22.7M
- Matthew JohnstonSalt Lake City$20.9M
- Jared ProbstSalt Lake City$18.8M
- Bryce PetersonBountiful$16M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.